Catalyst Dossier · compiled by CeliA 🧫
HeartSciences Inc. (HSCS)
Finance Services · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-30 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-09-30 (est.)Phase 2 · Dapagliflozin 10 MG [Farxiga]imp 7/10
- 2026-11-15 (est.)Phase 3 · Tadalafilimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Standard medical therapy | Phase 3 | Heart Failure |
| Levofloxacin | Phase 2 | Sarcoidosis; Antimycobacterial Therapy |
| BIO-11006 Inhalation Solution | Phase 2 | COPD |
| Secondary Prophylaxis | Phase 3 | Rheumatic Heart Disease |
| Atomoxetine | Phase 2 | Sleep Apnea |
| Dapagliflozin 10 MG [Farxiga] | Phase 2 | Chronic Kidney Diseases |
| Empagliflozin 10 MG | Phase 2 | Obesity |
| Chelation therapy | Phase 2 | Anemia (Iron-Loading) |
| Anakinra | Phase 2 | Heart Failure With Normal Ejection Fraction |
| Eszopiclone | Phase 3 | Sleep Apnea |
| Epi-743 | Phase 2 | Methylmalonic Aciduria and Homocystinuria,Cblc Type |
| Tadalafil | Phase 3 | Fontan Palliation |
| Surfactant | Phase 3 | Infant, Newborn, Diseases |
| AMD3100 | Phase 2 | Fanconi Anemia |
| amiodarone | Phase 3 | Atrial Fibrillation |
| LY3819253 | Phase 3 | Covid19 |
| clopidogrel | Phase 2 | Hypertension, Pulmonary |
| Esomeprazole | Phase 3 | Asthma |
| Tacrolimus | Phase 3 | Leukemia, Myelocytic, Acute |
| daily fluticasone propionate | Phase 3 | Asthma |
Price & technical context
3-month
+73.8%
6-month
+8.7%
12-month
-9.6%
52-wk range
$1.67–$3.75
vs 50-day MA
+26.7%
vs 200-day MA
+24.0%
Realized vol
89.4%
Max drawdown
-70.9%
Daily closes through 2026-08-27. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HSCS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.